Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extended photo-induced endosome-like structures in giant vesicles promoted by block-copolymer nanocarriers.

Nanoscale·2018
Same author

Intrathoracic pancreatic herniation: A rare cause of acute pancreatitis.

Diagnostic and interventional imaging·2018
Same author

Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study.

Seminars in arthritis and rheumatism·2018
Same author

Adult hypophosphatasia.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2018
Same author

Hybrid vesicles from lipids and block copolymers: Phase behavior from the micro- to the nano-scale.

Colloids and surfaces. B, Biointerfaces·2018
Same author

[Erratum to "Histoplasma capsulatum bone and joint infection" [Med. Mal. Infect. 47 (2017) 554-557]].

Medecine et maladies infectieuses·2017
Same journal

[Atypical low back pain].

La Revue de medecine interne·2026
Same journal

[Polycythemia associated chronic haemolysis].

La Revue de medecine interne·2026
Same journal

[Persistent headaches in a 55 year-old man].

La Revue de medecine interne·2026
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats
05:55

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

[Corticosteroid-induced osteoporosis].

K Briot1, C Roux

  • 1Service de rhumatologie, université Paris Descartes, hôpital Cochin, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France. karine.briot@cch.aphp.fr

La Revue De Medecine Interne
|December 15, 2012
PubMed
Summary
This summary is machine-generated.

Corticosteroid-induced osteoporosis is a common secondary form, affecting bone early and linked to dose. Prevention and treatment are crucial for patients on glucocorticoids, with bisphosphonates and parathyroid hormone showing efficacy.

More Related Videos

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

Related Experiment Videos

Last Updated: May 16, 2026

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats
05:55

Tension-Free Weight-Bearing Model of Steroid-Induced Osteonecrosis of Femoral Head in Rats

Published on: September 27, 2024

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome
05:18

Ultrasound-Guided Needle Release Combined with Corticosteroid Injection for the Treatment of Supinator Syndrome

Published on: May 26, 2023

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Context:

  • Corticosteroid-induced osteoporosis (CIOC) is the most prevalent secondary osteoporosis and a leading cause in younger individuals.
  • Bone loss begins early in corticosteroid therapy, correlating with dosage and duration.
  • Underlying inflammation associated with glucocorticoid use also negatively impacts bone health.

Purpose:

  • To review the pathogenesis, risk factors, and management strategies for corticosteroid-induced osteoporosis.
  • To emphasize the importance of early prevention and treatment in patients initiating glucocorticoid therapy.
  • To highlight current treatment options and guidelines for CIOC.

Summary:

  • CIOC is characterized by rapid bone loss, influenced by glucocorticoid dose and treatment length.
  • Prevention is recommended for all patients starting glucocorticoids, especially those on at least 7.5mg prednisone equivalent daily for over 3 months.
  • Bisphosphonates and parathyroid hormone (1-34) are effective treatments for CIOC.

Impact:

  • CIOC is frequently under-diagnosed and under-treated, necessitating greater clinical awareness and adherence to guidelines.
  • Individualized treatment duration for osteoporosis is essential, considering patient-specific factors and inflammatory disease progression.
  • Effective management of CIOC can mitigate fracture risk and improve long-term bone health in patients on glucocorticoids.